Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study
Headache: The Journal of Head and Face Pain,  Clinical Article

Derosier F et al. – This study primarily included subjects whose migraines significantly impacted their lives. Before the study, these subjects used butalbital–containing medications as part of their current migraine treatment regimen and were satisfied with it, suggesting they were butalbital responders who had found a workable treatment strategy for themselves. When treated with SumaRT/Nap versus BCM in this study, however, a significant proportion of subjects reported better treatment outcomes for themselves for both migraine pain and associated symptoms. Use of SumaRT/Nap was also associated with less rescue medication use and a longer time before use of rescue medication compared with both BCM and placebo.

Methods
  • Enrolled subjects were required to have treated at least 1 migraine with a butalbital medication in the past.
  • Enrolled subjects treated 3 moderate to severe migraines using each of the 3 study treatments once in a randomized sequence.
  • The primary endpoint compared SumaRT/Nap versus BCM for sustained pain freedom at 2–24 hours without the use of any rescue medication.
  • This study combines data from 2 identical outpatient, randomized, multicenter, double–blind, double–dummy, 3 attack crossover studies in adult migraineurs (International Classification of Headache Disorders, 2nd edition).

Results
  • A total of 442 subjects treated at least 1 attack with study medication.
  • The majority of the treated subjects were female (88%) with a mean age 43 years, who reported that their migraines had a severe impact on their lives (78% with Headache Impact Test–6 of >59).
  • At screening, 88% of subjects reported current butalbital use; 68% had used butalbital for more than 6 weeks; and 82% reported satisfaction with butalbital.
  • Across treatment groups, 28–29% of subjects took study medication within 15 minutes of migraine onset, 34–37% of subjects took study medication >15 minutes to 2 hours after onset, and 32–36% of subjects took study medication more than 2 hours after onset.
  • This study did not detect a difference at the nominal 0.05 level in percent sustained pain–free between SumaRT/Nap (8%), BCM (6%), and placebo (3%).
  • SumaRT/Nap was superior to BCM for pain free at 2, 4, 6, 8, 24, 48 hours (P ≤ .044); pain relief (mild or no pain) at 2, 4, 6, 8, 24, 48 hours (P ≤ .01); sustained pain relief 2–24 hours (P < .001); migraine free (pain free with no nausea, photophobia, or phonophobia) at 4, 6, 8, 24, 48 hours (P ≤ .046); and complete symptom free (migraine free with no neck/sinus pain) at 4, 6, 8, 48 hours (P ≤ .031).
  • Adverse event incidence was similar for all treatments (10%, 12%, and 9% for placebo, SumaRT/Nap, and BCM, respectively).
  • Nausea was the most frequent adverse event (2%, 2%, and <1% for placebo, SumaRT/Nap, and BCM, respectively).
  • Five serious adverse events were reported by 3 subjects: viral meningitis and colon neoplasm (placebo); chest pain and hypertension 17 days postdose (SumaRT/Nap); and breast cancer (BCM).
  • Investigators judged no serious adverse events related to study medication.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques Stroke, May 2, 2014    Clinical Article

2 Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis American Journal of Clinical Nutrition, June 19, 2014    Evidence Based Medicine    Review Article

3 Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses Canadian Journal of Cardiology, June 2, 2014    Evidence Based Medicine    Review Article    Clinical Article

4 Migraine, white matter hyperintensities, and subclinical brain infarction in a diverse community Stroke, June 13, 2014    Evidence Based Medicine    Clinical Article

5 Management of acute stroke in patients taking novel oral anticoagulants International Journal of Stroke, June 6, 2014    Clinical Article

6 Omega-3 fatty acids moderate effects of physical activity on cognitive function Neuropsychologia, June 9, 2014    Clinical Article

7 Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis Journal of Alzheimer’s Disease, April 2, 2014    Evidence Based Medicine    Review Article    Clinical Article

8 Vitamin D and subclinical cerebrovascular disease the atherosclerosis risk in communities brain magnetic resonance imaging study JAMA Neurology, June 11, 2014    Clinical Article

9 Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer's disease: A randomized, double-blind, placebo-controlled trial Biological Psychiatry, April 4, 2014    Clinical Article
Exclusive Author Commentary

10 Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives The Lancet, June 23, 2014    Review Article    Clinical Article

11 Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants--translating clinical trial data into practice Journal of Interventional Cardiac Electrophysiology , June 5, 2014    Clinical Article

12 Fruits and vegetables consumption and risk of stroke Stroke, May 28, 2014    Evidence Based Medicine

13 Maternal dietary intake of folate and vitamins B6 and B12 during pregnancy and risk of childhood brain tumors Nutrition and Cancer, June 17, 2014    Clinical Article

14 The ASCOMALVA (association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease) trial: Interim results after two years of treatment Journal of Alzheimer’s Disease, June 4, 2014    Clinical Article

15 Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use European Journal of Neurology, June 10, 2014    Clinical Article

16 Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? Thrombosis and Haemostasis, January 17, 2014    Clinical Article

17 Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study European Journal of Neurology, June 3, 2014    Clinical Article

18 The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials European Journal of Emergency Medicine, January 10, 2014    Evidence Based Medicine    Review Article    Clinical Article

19 Risk of stroke associated with nonsteroidal anti-inflammatory drugs Full Text Vascular Health and Risk Management, January 13, 2014    Free full text    Review Article    Clinical Article

20 Which drug should we use for stroke prevention in atrial fibrillation Current Opinion in Cardiology, June 9, 2014    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close